Evidence map›Paper›PMID 40206642›Full record

ArticleFrontiers in systems biology2024

Building an Adverse Outcome Pathway network for COVID-19.

Penny Nymark, Laure-Alix Clerbaux, Maria-João Amorim, Christos Andronis, Francesca de Bernardi, Gillina F G Bezemer, Sandra Coecke, Felicity N E Gavins, Daniel Jacobson, Eftychia Lekka and 10 more

Abstract read
In one paragraph

Article in Frontiers in systems biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Penny NymarkInstitute of Environmental Medicine, Karolinska Institute, Stockholm, Sweden.
Laure-Alix ClerbauxInstitute of Clinical and Experimental Research (IREC), UCLouvain, Brussels, Belgium.
Maria-João AmorimResearch Centre, Universidade Católica Portuguesa, Lisboa, Portugal.
Christos AndronisBiovista, Athens, Greece.
Francesca de BernardiDivision of Otorhinolaryngology, Department of Biotechnologies and Life Sciences, University of Insubria, Ospedale di Circolo e Fondazione Macchi, Varese, Italy.
Gillina F G BezemerImpact Station, Hilversum, Netherlands.
Sandra CoeckeEuropean Commission, Joint Research Centre (JRC), Ispra, Italy.
Felicity N E GavinsThe Centre for Inflammation Research and Translational Medicine, Brunel University London, London, United Kingdom.
Daniel JacobsonBiosciences, Oak Ridge National Laboratory, Oak Ridge, TN, United States.
Eftychia LekkaBiovista, Athens, Greece.
Luigi Margiotta-CasaluciKing's College London, London, United Kingdom.
Marvin MartensDepartment of Bioinformatics (BiGCaT), NUTRIM, Maastricht University, Maastricht, Netherlands.
Sally A MayasichAquatic Sciences Center, University of Wisconsin-Madison at US EPA, Duluth, MN, United States.
Holly M MortensenU.S. Environmental Protection Agency (US EPA), Research Triangle Park, NC, United States.
Young Jun KimEnvironmental Safety Group, KIST Europe, Saarbrucken, Germany.
Magdalini SachanaEnvironment Health and Safety Division, Environment Directorate, Organisation for Economic Cooperation and Development (OECD), Paris, France.
Shihori TanabeNational Institute of Health Sciences, Kawasaki, Japan.
Vassilis VirvilisBiovista, Athens, Greece.
Stephen W EdwardsRTI International, Research Triangle Park, NC, United States.
Sabina HalappanavarEnvironmental Health Science and Research Bureau, Health Canada, Ottawa, ON, Canada.

Funding

Intramural EPA EPA999999
6 · The paper itself

Abstract

The COVID-19 pandemic generated large amounts of data on the disease pathogenesis leading to a need for organizing the vast knowledge in a succinct manner. Between April 2020 and February 2023, the CIAO consortium exploited the Adverse Outcome Pathway (AOP) framework to comprehensively gather and systematically organize published scientific literature on COVID-19 pathology. The project considered 24 pathways relevant for COVID-19 by identifying essential key events (KEs) leading to 19 adverse outcomes observed in patients. While an individual AOP defines causally linked perturbed KEs towards an outcome, building an AOP network visually reflect the interrelatedness of the various pathways and outcomes. In this study, 17 of those COVID-19 AOPs were selected based on quality criteria to computationally derive an AOP network. This primary network highlighted the need to consider tissue specificity and helped to identify missing or redundant elements which were then manually implemented in the final network. Such a network enabled visualization of the complex interactions of the KEs leading to the various outcomes of the multifaceted COVID-19 and confirmed the central role of the inflammatory response in the disease. In addition, this study disclosed the importance of terminology harmonization and of tissue/organ specificity for network building. Furthermore the unequal completeness and quality of information contained in the AOPs highlighted the need for tighter implementation of the FAIR principles to improve AOP findability, accessibility, interoperability and re-usability. Finally, the study underlined that describing KEs specific to SARS-CoV-2 replication and discriminating physiological from pathological inflammation is necessary but requires adaptations to the framework. Hence, based on the challenges encountered, we proposed recommendations relevant for ongoing and future AOP-aligned consortia aiming to build computationally biologically meaningful AOP networks in the context of, but not limited to, viral diseases.

Indexed as

adverse outcome pathway (AOP)COVID-19eventinflammationnetwork

Identifiers

PMID40206642
PMCPMC11977783

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.